v3.22.2.2
Equity Transactions (Details Narrativeq) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 01, 2021
Feb. 08, 2021
Jul. 02, 2020
Jun. 28, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Sep. 26, 2022
Jul. 01, 2020
Common stock shares authorized         100,000,000 100,000,000        
Common stock shares par value         $ 0.001 $ 0.001        
Common stock shares outstanding         16,713,345 15,262,394        
Common stock shares issued                 4,642,888  
Common stock issued during period for cash, value           $ 127,500        
Net (loss) income         $ (2,046,030) $ 2,978,948        
Sale of common stock to underwriters         16,713,345 15,262,394        
Gross proceeds from sale of stocks         $ 0 $ 50,000        
Preferred stock shares issued         500,000 500,000        
Preferred stock shares authorized         100,000,000 100,000,000        
Preferred stock shares authorized, par value         $ 0.001 $ 0.001        
Preferred stock purchase price         $ (1,975,888) $ 0        
Trunano Labs, Inc. Common Stock [Member]                    
Convertion of shares into common stocks noncontrolling shareholders     1,761,261              
Outstanding stock conversion     1,277,778              
Common stock, percentage of outstanding shares     10.8              
Common stock shares authorized                   10,000,000
Common stock shares par value                   $ 0.001
Common stock shares outstanding                   7,261,261
Common stock shares issued                   7,261,261
Common stock issued during period for cash, value             $ 300,000 $ 1,655,000    
Common stock issued during period for cash, shares             270,270 1,490,991    
Net (loss) income             $ 5,850      
Issued and outstanding shares of common stock owned           5,500,000        
Common Stocks [Member]                    
Common stock shares authorized   20,000,000                
Common stock shares issued 306,935                  
Common stock shares purchase price per share   $ 4.50                
Common stock percentage offered to the public   15                
Sale of common stock to underwriters       2,530,000            
Sale of common stock to underwriters upon the full exercise of the option       330,000            
Gross proceeds from sale of stocks       $ 12,650,000            
Net proceeds after deducting the underwriting commissions, discounts, and offering expenses payable       $ 10,950,315            
Common stock issued during period for acquisition of Infusionz 83,334                  
Common stock issued during period for acquisition value $ 127,500                  
Acquisition liability $ 1,764,876                  
Convertible Preferred Stock [Member]                    
Preferred stock shares issued           500,000        
Preferred stock convertible into shares of common stock ratio           preferred stock is convertible into the Company’s common stock at a ratio of 1.8 shares of preferred stock for a single share        
Preferred stock converted into shares of common stock           500,000        
Number of common stock shares converted           277,778        
Preferred stock shares authorized           1,000,000        
Preferred stock shares authorized, par value           $ 0.001        
Preferred stock purchase price           $ 50,000        
Proceeds from shares sold         $ 50,000          
Infusionz [Member] | Common Stocks [Member]                    
Common stock issued during period for acquisition of Infusionz           526,404        
Common stock issued during period for acquisition value           $ 1,235,124